Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

Q3 2021 13F Holders as of 30 Sep 2021

Type / Class
Equity / Common Stock
Shares outstanding
56,078,244
Total 13F shares
24,374,413
Share change
-1,022,716
Total reported value
$206,301,397
Put/Call ratio
213%
Price per share
$8.46
Number of holders
89
Value change
-$11,175,534
Number of buys
34
Number of sells
49

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q3 2021

As of 30 Sep 2021, Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by 89 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 24,374,413 shares. The largest 10 holders included Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., BOXER CAPITAL, LLC, Artal Group S.A., VANGUARD GROUP INC, FEDERATED HERMES, INC., MORGAN STANLEY, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). This page lists 89 institutional shareholders reporting positions in this security for the Q3 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.